Body Composition Is Improved During 12 Months' Treatment With Metformin Alone or Combined With Oral Contraceptives Compared With Treatment With Oral Contraceptives in Polycystic Ovary Syndrome

Glintborg, Dorte; Altinok, Magda Lambaa; Mumm, Hanne; Hermann, Anne Pernille; Ravn, Pernille; Andersen, Marianne

doi:10.1210/jc.2014-1135

Cited by 71 publications

(89 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In meta-analyses, treatment with oral contraceptives was associated with unchanged fasting insulin in PCOS (62), but fasting insulin is only a rough measure of insulin resistance (13) and different generation oral contraceptives could have divergent effects on metabolic risk (63). One year´s treatment with a third-generation oral contraceptive was associated with a median weight gain of 1.2 kg, which was evenly distributed on the upper and lower body regions and was unassociated with changes in testosterone levels (64). Currently, treatment with a second-generation oral contraceptives is often a first choice in patients with PCOS due to low thromboembolic risk (65,66), but the antiandrogen effect of newer generations of oral contraceptives could have less adverse effects on insulin resistance (67).…”

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Glintborg

Andersen

2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in premenopausal women. The syndrome is characterized by hyperandrogenism, irregular menses and polycystic ovaries when other etiologies are excluded. Obesity, insulin resistance and low vitamin D levels are present in more than 50% patients with PCOS, these factors along with hyperandrogenism could have adverse effects on long-term health. Hyperinflammation and impaired epithelial function were reported to a larger extent in women with PCOS and could particularly be associated with hyperandrogenism, obesity and insulin resistance. Available data from register-based and data linkage studies support that metabolic-vascular and thyroid diseases, asthma, migraine, depression and cancer are diagnosed more frequently in PCOS, whereas fracture risk is decreased. Drug prescriptions are significantly more common in PCOS than controls within all diagnose categories including antibiotics. The causal relationship between PCOS and autoimmune disease represents an interesting new area of research. PCOS is a lifelong condition and long-term morbidity could be worsened by obesity, sedentary way of life, Western-style diet and smoking, whereas lifestyle intervention including weight loss may partly or fully resolve the symptoms of PCOS and could improve the long-term prognosis. In this review, the possible implications of increased morbidity for the clinical and biochemical evaluation of patients with PCOS at diagnosis and follow-up is further discussed along with possible modifying effects of medical treatment.

show abstract

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Glintborg

Andersen

2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Important treatment options that influence hyperandrogenism and insulin sensitivity are available for PCOS, while long-term treatment options for PCOS are still controversial [9]. The aim of treatment of PCOS is to decrease hyperandrogenism and improve insulin sensitivity [9].…”

Section: Introductionmentioning

confidence: 99%

“…The aim of treatment of PCOS is to decrease hyperandrogenism and improve insulin sensitivity [9]. Insulin-sensitizers, oral contraceptive pills, and anti-androgenic agents are used commonly for the treatment of PCOS [10, 11].…”

Section: Introductionmentioning

confidence: 99%

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Karateke¹,

Dokuyucu²,

Doğan

et al. 2018

Med Princ Pract

View full text Add to dashboard Cite

Objective: Polycystic ovary syndrome (PCOS) is a serious endocrine disorder. In the present study, we investigated the therapeutic effects of erdosteine in letrozole-induced PCOS in rats. Methods: Thirty-two Wistar albino female rats were grouped as control group (C), PCOS group (PCOS), PCOS-metformin group (PCOS+MET), and PCOS-erdosteine group (PCOS+Erd). PCOS was induced by administering letrozole; such rats presented with sex hormone disorder, abnormal estrous cycles determined by daily vaginal smear, large cystic follicles, and increasing fasting insulin levels. After induction of PCOS, metformin (500 mg/kg/day) and erdosteine (100 mg/kg/day) were given orally to the treatment groups for 30 days. Serum concentrations of glucose, total cholesterol, low- and high-density lipoprotein, triglyceride, as well as the total oxidant and antioxidant status, oxidative stress index, circulating estrone (E1), estradiol (E2), testosterone, and androstenedione were evaluated. The ovaries were graded histologically. Results: Weights of ovarian tissues (p < 0.05) and the number of atretic follicles (p < 0.001) and cystic follicles (p < 0.01) decreased in the PCOS+Erd group; the corpus luteum number was significantly higher in the PCOS+Erd group (p < 0.01) as compared with the PCOS group. Lipid parameters (total-C, LDL-C, and TG), E1 (estrone), E1/E2 ratio, testosterone, and androstenedione significantly decreased, while HDL-C and E2 (estradiol) significantly increased in the PCOS+Erd group as compared with the PCOS group. Moreover glucose, insulin, and HOMA-IR were reduced with treatment of erdosteine (p > 0.05, p < 0.001, and p < 0.001, respectively). Conclusion: It is suggested that erdosteine may be used in the treatment of PCOS as an alternative to metformin. It appears that our findings might be supported by clinical and molecular studies.

show abstract

“…Placebóval és életmód-változtatással összeha-sonlítva legalább 8 hetes kezelés során a BMI szerény ÖSSZEFOGLALÓ KÖZLEMÉNY mértékben, de szignifi kánsan csökkent (WMD: -0,68 [95% CI: (-1,13) -(-0,24)]) [25]. A kezelési idő meghosszabbítása nem növelte az eredményességet, 12 hó-napos MET-kezelés alatt a testtömegcsökkenés mediánja 3 kg volt (25-75 percentilis: -10,3-0,6) [26].…”

Section: A Metformin Alkalmazásaunclassified

A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája

Gődény

Csenteri

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A polycystás ovarium szindróma a nők leggyakoribb endokrin és anyagcsere-betegsége. A különböző klinikai formá-ban jelentkező betegség kardinális tünetei közé tartoznak a hiperandrogén bőrtünetek és/vagy emelkedett szérum-androgénszintek, oligo-vagy amenorrhoea, anovuláció miatt kialakuló meddőség és esetenként a petefészek polycystás szerkezete. A szindróma kezelése függ a klinikai megjelenéstől, az életkortól, az alkalmazott diagnosztikus technológiák pontosságától, valamint attól, hogy mely kritériumrendszer alkalmazásával történt a diagnózis felállítá-sa. A bizonyítékon alapuló, megfelelően kiválasztott terápiás technológiával javul a kórkép kezelésének eredményes-sége, hatékonysága, a betegek biztonsága, életminősége és várható élettartama. A közlemény a rendelkezésre álló irodalmi adatok, elsősorban a legmagasabb szintű bizonyítékoknak tekinthető szisztematikus irodalmi áttekintések és metaanalízisek felhasználásával ismerteti a szindrómához társuló tünetek, az elhízás, a hyperandrogenismus, a vér-zészavarok, a meddőség és a lelki problémák kezelésének lehetőségeit. Orv. Hetil., 2015, 156(45), 1803-1815. Kulcsszavak: PCOS, klinikai tünetek, EBM, terápia Evidence-based therapy of polycystic ovarian syndromePolycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women. The heterogeneous endocrinopathy is characterized by clinical and/or biochemical hyperandrogenism, oligo-or amenorrhoea, anovulatory infertility, and polycystic ovarian morphology. The syndrome is often associated with obesity, hyperinsulinemia and adversely affects endocrine, metabolic, and cardiovascular health. The symptoms and complaint of the patients vary with age. To maximise health gain of the syndrome, adequate, evidence based effective, effi cient and safe treatment is necessary. This article summarises the highest available evidence provided by studies, meta-analysis and systematic reviews about the therapeutical possibilities for treating obesity, hyperandrogenism, menstrual abnormalities, infertility and psychological problems related to polycystic ovary syndrome ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések 2TDM = 2-es típusú diabetes mellitus; A = androsztendion; BMI = (body mass index) testtömegindex; CC = clomifen-citrát; CPA = ciproteron-acetát; CI = (confi dence interval) megbízhatósági tartomány, konfi denciaintervallum; DHEAS = dehidroepiandroszteron-szulfát; DHT = dihidro-tesztoszteron; DRSP = drospirenon; EBM = (evidence-based medicine) bizonyítékokon alapuló orvoslás; EE = etinil-ösztradiol; EE+CPA = etinil-ösztradiolt és ciproteron-acetátot tartalmazó kombinált készítmény; EE+DRSP = etinil-ösztradiolt és drospirenont tartalmazó kombinált készítmény; EMA = (European Medicines Agency) Európai Gyógyszerügynökség; FAI = (free androgen *A Debreceni Egyetem, Klinikai Központ, Szülészeti és Nőgyógyászati Klinika endokrin munkacsoportjának tagja.

show abstract

Body Composition Is Improved During 12 Months' Treatment With Metformin Alone or Combined With Oral Contraceptives Compared With Treatment With Oral Contraceptives in Polycystic Ovary Syndrome

Cited by 71 publications

References 30 publications

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

A polycystás ovarium szindróma tüneteinek bizonyítékokon alapuló terápiája

Contact Info

Product

Resources

About